Ursprung des Netzwerks ersten Grades von Roman Schenk
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Recardio, Inc.
 Recardio, Inc. Pharmaceuticals: MajorHealth Technology Recardio, Inc. operates as a clinical-stage life science company that focuses on therapies for cardiovascular, oncology, and infectious diseases. The company was founded by Roman Schenk and is headquartered in San Francisco, CA.
1
| Private Company | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Roman Schenk
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| NEPHROGENEX INC | Medical Distributors | Chief Operating Officer | |
CardioPolymers, Inc.
 CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Pharmaceuticals: Major | Chief Operating Officer | |
| The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin | |
| The University of Texas at Austin | College/University | Undergraduate Degree | |
| Chimeric Therapies, Inc. | Corporate Officer/Principal | ||
| EDWARDS LIFESCIENCES CORPORATION | Medical Specialties | Corporate Officer/Principal | |
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Medical Specialties | Chief Executive Officer |
Statistik
International
| Vereinigte Staaten | 10 |
Sektoral
| Health Technology | 4 |
| Distribution Services | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Operativ
| Chief Operating Officer | 4 |
| President | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Frank A. Ahmann | 10 |
- Börse
- Insiders
- Roman Schenk
- Unternehmensverbindungen
